Vaccibody has in a new share issue completed a 35 MNOK (4.3 million €) financing from existing and new investors. The share issue was significantly oversubscribed. The largest new investor is represented by Datum and partners, which will take a seat in the Board of Directors. The previously announced investment from the Norwegian Cancer Society was instrumental in the process. Arctic Securities is the manager for the share issue. The finalization will take place in the extraordinary general meeting on July 9th.
“We are very pleased to see such a great interest in Vaccibody AS and I look forward to take the Company into a new stage by initiating our first clinical study. I very much welcome our new strong investor group and look forward to a fruitful collaboration in the years to come.” CEO, Ole Henrik Brekke
For further information please contact:
CEO Ole Henrik Brekke, ohbrekke@vaccibody.com, +4792628434
